Medical Predictive Science

What Medical Predictive Science does

Medical Predictive Science Corporation (MPSC), operating commercially as "HeRO by MPSC," is a privately held medical device company founded in 2003 and headquartered in Charlottesville, Virginia. The company commercializes a proprietary heart rate characteristics (HRC) algorithm — originally developed at the University of Virginia and protected by US and Canadian patents — that analyzes continuous heart rate variability data from premature infants in neonatal intensive care units (NICUs) to detect early signs of sepsis, necrotizing enterocolitis, urinary tract infection, meningitis, respiratory decompensation, and brain pathology hours before clinical symptoms emerge. The flagship HeRO Score is an hourly numeric risk score that has been validated in a 3,003-infant randomized controlled trial — the largest ever conducted in neonatology — demonstrating a 22% overall mortality reduction, 40% mortality reduction in infected babies, and a 3.2-day length-of-stay reduction.

MPSC offers a portfolio of HeRO-branded products: HeRO Symphony for central networked monitoring, HeRO solo and HeRO duet as cost-effective bedside monitors, and HeRO ES as an embedded system running within Philips IntelliVue MX monitors. Revenue is generated primarily through hardware sales and associated clinical decision support software under multi-year contracts, with pricing quoted on a deal-by-deal basis. Go-to-market combines a direct enterprise sales team in the United States with exclusive international distributors covering 26 countries across Europe, the Middle East, North America, and the Caribbean. The company holds FDA 510(k) clearance, CE marking, and Health Canada Medical Device License, and is developing HeRO NOWS (FDA Breakthrough Device, July 2024) and a neonatal nutrition clinical decision support system backed by NIH funding.

Name

Medical Predictive Science

Legal name

Medical Predictive Science Corporation

Website

https://heroscore.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Short description

Medical Predictive Science Corporation (MPSC), dba HeRO by MPSC, is a Charlottesville, VA medical device company that commercializes a proprietary heart rate variability algorithm — the HeRO Score — to provide early warning of sepsis and other life-threatening conditions in premature infants in hospital NICUs, with products available in 26 countries.

Ownership category

akta.pro rank

Product category

Neonatal Patient Monitoring

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAHACAF

Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

SECONDARYHLACAPAG

Maternal, Neonatal & Pediatric Remote Monitoring

Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

SECONDARYHLACAFAC

Maternal & Neonatal Remote Monitoring Platforms

Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

SECONDARYHLACAGAE

Risk Stratification, Early Warning Scores & Predictive Analytics

Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

• Neonatal patient monitoring
• Heart rate variability analysis
• Predictive analytics healthcare
• NICU sepsis detection
• Clinical decision support

Headquarters

HQ city

Charlottesville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. HeRO Monitoring Hardware and Software: MPSC generates revenue through the sale of HeRO monitoring devices and associated software. Product line includes HeRO Symphony (central monitoring), HeRO solo and duet (bedside solutions), and HeRO ES (embedded in Philips monitors). The company sells directly to hospitals and through international distributors.
2. Clinical Decision Support Software: Revenue from clinical decision support tools including the HeRO monitoring system and associated algorithms that provide diagnostic information and decision support to physicians

Pricing tiers

Go-to-market motion2 records

Distribution channels8 records

Marketing channels7 records

Core offering

Medical Predictive Science Corporation develops and sells the HeRO (Heart Rate Observation) family of AI-based predictive monitoring systems for neonatal intensive care units (NICUs). The proprietary Heart Rate Characteristics (HRC) algorithm analyzes continuous heart rate variability data from existing patient monitors to generate an hourly HeRO Score quantifying a preterm infant's risk of sepsis, NEC, UTI, meningitis, respiratory decompensation, brain pathology, and death up to 24 hours in advance. Products are deployed in hospitals across 26 countries and are FDA cleared, CE marked, and Health Canada licensed.

Product overview

Medical Predictive Science Corporation (MPSC) offers the HeRO (Heart Rate Observation) product line — a family of AI-based predictive monitoring systems for the Neonatal Intensive Care Unit (NICU). The portfolio includes HeRO Symphony (central networked system), HeRO solo and HeRO duet (cost-effective bedside monitors), and HeRO ES (embedded within Philips IntelliVue MX monitors). All HeRO products share the same core HeRO Score algorithm, which analyzes heart rate variability to detect early signs of sepsis, infection, and other forms of deterioration in premature infants hours before clinical symptoms appear. MPSC also offers free online extubation prediction tools and is developing HeRO NOWS for neonatal opioid withdrawal syndrome detection (FDA Breakthrough Device designated).

Differentiator

Problem solved

Functional benefit

Brands

• HeRO Symphony: The most advanced form of HeRO monitoring system, sets the paradigm for the HeRO System.
• HeRO solo
• HeRO duet
• HeRO ES
• HeRO NOWS
• Clinical Decision Support

Quantifiable outcome

• 22% reduction in mortality for HeRO monitored premature infants in randomized controlled trial of 3,003 very low birth weight babies
• +6 more outcomes

Named customers10 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core, regional and minor.

• University of Virginia Children's HospitalcoreStrategic or Co-development Partner · 1 October 2023Research collaboration with neonatology researchers at UVA studying cardiorespiratory signatures of NOWS; part of $3.1M NIH award for HeRO NOWS development.
• Stanley Manne Children's Research Institute / Ann & Robert H. Lurie Children's Hospital of ChicagocoreStrategic or Co-development Partner · 10 September 2022NIH STTR grant collaboration with Dr. Gustave Falciglia to develop clinical decision support system for optimizing nutrition for neonatal growth in the NICU.
• Tomorrow MedicalcoreChannel Partner/ Reseller/ Distributor · 7 June 2019Exclusive distribution agreement for HeRO products in Netherlands, Germany, and Belgium. Tomorrow Medical aims to extend and improve life by early treatment of health risks, providing highest quality service to customers and patients in the Benelux and DACH regions.
• CEMSAregionalChannel Partner/ Reseller/ Distributor · 20 May 2019Distributor for Mexico representing HeRO in the growing number of countries where HeRO is available. CEMSA is working to obtain necessary regulatory clearances for HeRO sale into Mexico.
• Euromed ItalyregionalChannel Partner/ Reseller/ DistributorItalian distributor that placed first order for HeRO duet, collaborating to introduce HeRO into the Italian market.
• SLE LtdregionalChannel Partner/ Reseller/ DistributorUK distributor that helped Singleton Hospital successfully receive innovation grant to deploy HeRO System in their NICU.
• MeditechregionalChannel Partner/ Reseller/ DistributorJamaican distributor located in Kingston that placed HeRO duet unit at University Hospital of the West Indies, expanding HeRO presence in the Caribbean.
• Philips HealthcarecoreTechnology or IntegrationHeRO ES is an embedded HeRO System that runs within specific Philips IntelliVue MX monitors, providing integrated monitoring solution leveraging existing hospital monitoring infrastructure.
• Washington University in St. LouiscoreStrategic or Co-development PartnerCollaborating research institution studying cardiorespiratory signatures of NOWS as part of the HeRO NOWS development team.
• University of Alabama at BirminghamcoreStrategic or Co-development PartnerPart of research team studying cardiorespiratory signatures of NOWS and long-time HeRO customer; collaborated on multiple clinical studies.
• March of DimesminorGTM or Marketing PartnerMPSC sponsors March of Dimes Conference for Health Professionals which focuses on improvement of neonatal outcomes.
• Virginia Economic Development Partnership (VEDP)minorGTM or Marketing PartnerPartnership supporting MPSC's international presence at trade shows including Arab Health conference, Virginia Pavilion.
• Patient Safety Movement FoundationminorGTM or Marketing PartnerMPSC signed Open Data Pledge to share data for patient safety; committed to eliminating preventable patient deaths.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Masimo: Masimo is a leading patient monitoring company whose SET pulse oximetry and recent SedLine / RD rainbow sensors occupy overlapping clinical footprint with HeRO (bedside sensor-based monitoring used in NICU/ICU). Both companies develop physiology-derived early-warning indices running on or alongside bedside monitors, and both target clinician decisions in critical-care environments.
• Etiometry: Etiometry provides AI-based clinical decision support software that aggregates physiologic data streams from ICU monitors to predict patient deterioration in pediatric and neonatal ICUs. Both companies sell early-warning analytics that consume continuous bedside monitor data to flag risk of deterioration hours in advance, serving the same neonatology buyer.

Broad incumbents

• Philips Healthcare: Philips is the dominant NICU patient monitor manufacturer (IntelliVue MX) and MPSC's existing OEM partner for HeRO ES embedded analytics. Philips is the broad incumbent whose installed base MPSC leverages and whose competitive moves (e.g., native analytics) most directly affect HeRO's commercial outlook.
• GE HealthCare: GE HealthCare is a global leader in patient monitoring (CARESCAPE) and a competitor for NICU monitoring capital budgets. It competes broadly with Philips/MPSC for the bedside and central monitoring footprint that HeRO's algorithms run on top of.
• Dräger: Dräger is a major NICU/ICU equipment and patient monitoring vendor with strong European share (Babylog/NICO). As a competing bedside monitor OEM with established NICU clinical relationships, Dräger represents both a partner channel and a competitive threat to HeRO's embedded software strategy.
• Nihon Kohden: Nihon Kohden is a global patient monitoring company with strong ICU/NICU presence and increasingly invests in AI-driven decision-support tools. It competes with MPSC for hospital physiology-monitoring budgets and could either partner or challenge HeRO at large IDNs.
• Medtronic: Medtronic is a major cardiac diagnostics and physiologic monitoring player (e.g., INVOS, vital sign monitoring investments). While not NICU-focused, it competes in the broader hospital AI/physiology-analytics category and could emerge as a strategic acquirer of NICU-focused analytics like HeRO.
• Spacelabs Healthcare: Spacelabs (now part of OSI Systems / acquired by Capitol Group) is a longstanding patient monitoring and clinical analytics vendor with substantial NICU installed base. Its XprezzNet and clinical decision support modules compete with HeRO at hospitals evaluating platform-level physiology analytics contracts.

Emerging players

• Dascena (Inflammatix): Dascena (now part of Inflammatix) developed AI-driven early-warning algorithms for inpatient deterioration (sepsis, AKI), analogous to HeRO's inflammation-driven HRC monitoring. Both companies pursue the same thesis — that subtle physiologic signatures enable earlier intervention — making them thematically comparable emerging players in clinical predictive analytics.
• Sickbay (by Biotricity): Biotricity's Sickbay platform aggregates continuous ICU waveform data from multiple bedside monitors to deliver analytics including early warning indicators. Like HeRO, Sickbay sits between bedside monitor hardware and clinical decision-making, providing physiology-based risk scores to ICU clinicians.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@HeROScore
• Xx.com/mpschero
• LinkedInlinkedin.com/company/medical-predictive-science-corp

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medical Predictive Science